A Clinical Review of Eslicarbazepine Acetate

Article Type
Changed
Mon, 12/06/2021 - 14:56

When managing seizures, physicians have multiple treatment choices developed over the past half century. Partial-onset seizures, or focal seizures, represent the majority of cases. Neurologists and primary care providers are tasked with choosing the first-, second-, or third-line option for monotherapy, and determining when treatment-refractory cases require adjunct treatment. 


This supplement reviews Eslicarbazepine Acetate and its effectiveness as a first-line or later adjunctive therapy in patients with partial-onset seizures.
 

Click here to read more

Sponsor
This supplement is supported by an independent medical education grant from Sun…
Sponsor Teaser Title Override
Sponsored Supplement
Publications
Sections
Sponsor
This supplement is supported by an independent medical education grant from Sun…
Sponsor
This supplement is supported by an independent medical education grant from Sun…

When managing seizures, physicians have multiple treatment choices developed over the past half century. Partial-onset seizures, or focal seizures, represent the majority of cases. Neurologists and primary care providers are tasked with choosing the first-, second-, or third-line option for monotherapy, and determining when treatment-refractory cases require adjunct treatment. 


This supplement reviews Eslicarbazepine Acetate and its effectiveness as a first-line or later adjunctive therapy in patients with partial-onset seizures.
 

Click here to read more

When managing seizures, physicians have multiple treatment choices developed over the past half century. Partial-onset seizures, or focal seizures, represent the majority of cases. Neurologists and primary care providers are tasked with choosing the first-, second-, or third-line option for monotherapy, and determining when treatment-refractory cases require adjunct treatment. 


This supplement reviews Eslicarbazepine Acetate and its effectiveness as a first-line or later adjunctive therapy in patients with partial-onset seizures.
 

Click here to read more

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry - Sponsored Supplement
Gate On Date
Tue, 07/20/2021 - 14:45
Un-Gate On Date
Tue, 07/20/2021 - 14:45
Use ProPublica
CFC Schedule Remove Status
Tue, 07/20/2021 - 14:45
Hide sidebar & use full width
render the right sidebar.
Sponsor Teaser Title Override
Sponsored Supplement
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article